EUCTR2007-007026-22-CZActive, not recruitingNot Applicable
Assessment of the effects on 24-hour ambulatory blood pressure and the safety of a once-a-day oral 8 mg perindopril morning administration versus evening administration in hypertensive patients. An 8-week, 2-arm, randomised, double-blind study.
Institut de Recherches Internationales Servier0 sites500 target enrollmentStarted: March 28, 2008Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Enrollment
- 500
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Essential hypertension after institution of appropriate healthy lifestyle modification, measured with a validated automatic measurement device in the medical office in supine position: 95 = DBP < 110 mmHg and SBP < 180 mmHg.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Kalaemia = local laboratory's high normal values
- •Positive pregnancy test for non menopausal women
- •Creatinine = 150 mmol/l or creatinine clearance < 60 ml/mn, using Cockroft's formula
Investigators
Similar Trials
Recruiting
Not Applicable
A clinical study of the relation between 24-hour intraocular pressure and activities.JPRN-UMIN000018273Saga university20
Recruiting
Phase 3
Evaluation of serum replacement frequency used in drug infusion on serum contamination and incidence of phlebitisIRCT20210307050610N1Sabzevar University of Medical Sciences300
Active, not recruiting
Not Applicable
A clinical trial to monitor the 24 hour intraocular pressure (IOP) with the help of a device named SENSIMED Triggerfish® in patients having primary angle closure and primary angle closure glaucoma before and after laser treatment (peripheral iridotomy)CTRI/2012/10/003067SENSIMED AG30
Active, not recruiting
Not Applicable
A 12-Week Study to Evaluate the 24 Hour Pulmonary Function of Fluticasone Furoate (FF)/Vilanterol (VI) Inhalation Powder (FF/VI Inhalation Powder) Once Daily Compared with Salmeterol/Fluticasone Propionate (FP) Inhalation Powder Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 13.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-021059-25-DEGlaxoSmithKline Research & Development Ltd520
Active, not recruiting
Phase 1
A 12-Week Study to Evaluate the 24 Hour Pulmonary Function of Fluticasone Furoate (FF)/Vilanterol (VI) Inhalation Powder (FF/VI Inhalation Powder) Once Daily Compared with Salmeterol/Fluticasone Propionate (FP) Inhalation Powder Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) 201EUCTR2010-021059-25-BEGlaxoSmithKline Research & Development Ltd520